Terran Biosciences announces acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals
Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals (“Concert”) to acquire a portfolio of Concert’s CNS therapeutics and accompanying intellectual property. These deuterated compounds represent next-generation therapeutics with applications across…
